Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-6bf8c574d5-b4m5d Total loading time: 0 Render date: 2025-02-23T06:33:19.695Z Has data issue: false hasContentIssue false

Citalopram

Published online by Cambridge University Press:  20 February 2025

K. Ray Chaudhuri ,
Peter Jenner ,
Valentina Leta ,
Shelley Jones  and
Iro Boura
K. Ray Chaudhuri
Affiliation:
King's College London
Peter Jenner
Affiliation:
King's College London
Valentina Leta
Affiliation:
King's College London
Shelley Jones
Affiliation:
King's College London
Iro Boura
Affiliation:
St. George General Hospital of Chania, Crete, Greece
Get access

Summary

Citalopram (1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile) is a fine white to off-white powder with a molecular weight of 324.4 and an empirical formula of C20H21FN2O. Citalopram 20 mg is equivalent to 24.99 mg citalopram hydrobromide.

Type
Chapter
Information
The Movement Disorders Prescriber's Guide to Parkinson's Disease , pp. 70 - 82
Publisher: Cambridge University Press
Print publication year: 2025

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Reading

Devos, D, Dujardin, K, Poirot, I, Moreau, C, Cottencin, O, Thomas, P, Destée, A, Bordet, R, Defebvre, L. Comparison of desipramine and citalopram treatments for depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2008; 23(6): 850–857.CrossRefGoogle Scholar
Menza, M, Marin, H, Kaufman, K, Mark, M, Lauritano, M. Citalopram treatment of depression in Parkinson’s disease: the impact on anxiety, disability, and cognition. J Neuropsychiatry Clin Neurosci 2004; 16(3): 315–319.CrossRefGoogle ScholarPubMed
Starkstein, SE, Brockman, S. Management of depression in Parkinson’s disease: a systematic review. Mov Disord Clin Pract 2017; 4(4): 470–477.CrossRefGoogle ScholarPubMed
Wermuth, L, Sørensen, PS, Timm, S, Christensen, B, Utzon, NP, Boas, J, Dupont, E, Hansen, E, Magnussen, I, Mikkelsen, B, Worm-Petersen, J, Lauritzen, L, Bayer, L, Bech, P. Depression in idiopathic Parkinson’s disease treated with citalopram: a placebo-controlled trial. Nordic J Psychiatry, 1998; 52(2): 163–169.CrossRefGoogle Scholar

References

Aga, VM. When and how to treat agitation in Alzheimer’s disease dementia with citalopram and escitalopram. Am J Geriatr Psychiatry 2019; 27(10): 1099–1107.CrossRefGoogle Scholar
AHFS Drug information 2012. Bethesda: American Society of Health-System Pharmacists. Accessed on 4 December 2022 via www.medicinescomplete.com.Google Scholar
Cipriani, A, Purgato, M, Furukawa, TA, Trespidi, C, Imperadore, G, Signoretti, A, Churchill, R, Watanabe, N, Barbui, C. Citalopram versus other anti-depressive agents for depression. Cochrane Database Syst Rev 2012; 7(7): Cd006534.Google Scholar
Citalopram. In: Brayfield, A (Ed.), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. Accessed on 4 December 2022 via www.medicinescomplete.com.Google Scholar
Citalopram. In: DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Accessed 4 December 2022 via www.micromedexsolutions.com.Google Scholar
Dell’Agnello, G, Ceravolo, R, Nuti, A, Bellini, G, Piccinni, A, D’Avino, C, Dell’Osso, L, Bonuccelli, U. SSRIs do not worsen Parkinson’s disease: evidence from an open-label, prospective study. Clin Neuropharmacol 2001; 24(4): 221–227.CrossRefGoogle Scholar
Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Accessed 4 December 2022 via www.medicinescomplete.com.Google Scholar
Montgomery, S, Hansen, T, Kasper, S. Efficacy of escitalopram compared to citalopram: a meta-analysis. Int J Neuropsychopharmacol 2011; 14(2): 261–268.CrossRefGoogle Scholar
Porsteinsson, AP, Drye, LT, Pollock, BG, Devanand, DP, Frangakis, C, Ismail, Z, Marano, C, Meinert, CL, Mintzer, JE, Munro, CA, Pelton, G, Rabins, PV, Rosenberg, PB, Schneider, LS, Shade, DM, Weintraub, D, Yesavage, J, Lyketsos, CG. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA 2014; 311(7): 682–691.CrossRefGoogle ScholarPubMed
Rampello, L, Chiechio, S, Raffaele, R, Vecchio, I, Nicoletti, F. The SSRI, citalopram, improves bradykinesia in patients with Parkinson’s disease treated with l-dopa. Clin Neuropharmacol 2002; 25(1): 21–24.CrossRefGoogle ScholarPubMed
Ryan, M, Eatmon, CV, Slevin, JT. Drug treatment strategies for depression in Parkinson disease. Expert Opin Pharmacother 2019; 20(11): 1351–1363.CrossRefGoogle ScholarPubMed
Sid-Otmane, L, Huot, P, Panisset, M. Effect of antidepressants on psychotic symptoms in Parkinson disease: a review of case reports and case series. Clin Neuropharmacol 2020; 43(3): 61–65.CrossRefGoogle ScholarPubMed
Summary of Product Characteristics – Cipramil 20 mg film-coated tablets. Lundbeck Limited. Electronic Medicines Compendium: Cipramil 20 mg film-coated tablets – Summary of Product Characteristics (SmPC) – (emc). Accessed on 4 December 2022 via www.medicines.org.uk.Google Scholar
Troeung, L, Egan, SJ, Gasson, N. A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson’s disease. PLoS One 2013; 8(11): e79510.CrossRefGoogle ScholarPubMed
Ye, Z, Altena, E, Nombela, C, Housden, CR, Maxwell, H, Rittman, T, Huddleston, C, Rae, CL, Regenthal, R, Sahakian, BJ, Barker, RA, Robbins, TW, Rowe, JB. Selective serotonin reuptake inhibition modulates response inhibition in Parkinson’s disease. Brain 2014; 137(4): 1145–1155.CrossRefGoogle ScholarPubMed
Zivin, K, Pfeiffer, PN, Bohnert, AS, Ganoczy, D, Blow, FC, Nallamothu, BK, Kales, HC. Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. Am J Psychiatry 2013; 170(6): 642–650.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Citalopram
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.009
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Citalopram
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.009
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Citalopram
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.009
Available formats
×